# Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

> **NCT05544591** · PHASE2 · COMPLETED · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 93 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** 611 Q2W
- **DRUG:** 611 Q4W
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT05544591
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-26
- **Primary completion:** 2023-07-10
- **Final completion:** 2023-09-20
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05544591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05544591, "Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05544591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*